#USA #Health Sector #Astrana Health #Alhambra #NASDAQ:ASTH

Astrana Health, Inc. Reports First Quarter 2025 Results

Astrana Health, Inc. (NASDAQ: ASTH), a leading provider-focused technology-powered healthcare company, has released its consolidated financial results for the first quarter ended March 31, 2025. The firm is dedicated to enhancing patient-centered care by utilizing cutting-edge technology that allows healthcare providers to deliver high-quality services efficiently and effectively.

Brandon Sim, President and CEO of Astrana Health, commented on the results, stating, "The robust performance in the first quarter represents our ongoing efforts to establish the leading patient-centered healthcare platform in the United States. With our distinctive clinical capabilities and a technology-enabled delegated model, we are steadily driving growth that is both profitable and sustainable. This is evident even in today’s complex regulatory environment, as we demonstrate that value-based care can yield significant impacts and long-term viability."

Financial Overview

Astrana's financial highlights for the first quarter of 2025 compared to the same period in 2024 display impressive growth:

• - Total revenue reached $620.4 million, marking a significant increase of 53% from $404.4 million a year earlier.
• - Care Partners revenue surged to $601.0 million, up 57% from $382.3 million.
• - The net income attributable to Astrana decreased to $6.7 million, down from $14.8 million.
• - Earnings per share (diluted) settled at $0.14, compared to $0.31 previously.
• - The adjusted EBITDA was reported at $36.4 million, a decline from $42.2 million.

An examination of Astrana's operational aspects revealed their commitment to enhancing their team to support growth objectives. The company has recently welcomed Georgie Sam, Chief Data Analytics Officer, who will lead the enterprise-wide data and analytics strategy, and Glenn Sobotka as Chief Accounting Officer, bringing robust expertise to advance financial oversight. Additionally, Rita Pew has stepped up as Chief People Officer, fostering a positive workplace culture essential for driving Astrana forward.

Furthermore, Astrana has successfully integrated Collaborative Health Systems (CHS) into its proprietary technology platform, which is already yielding operational efficiencies. The company has also received Hart-Scott-Rodino (HSR) approval for the upcoming acquisition of Prospect Health, which is expected to be finalized by this summer.

Segment Results

In terms of segment performance, the three months ended March 31, 2025 showed:

• - CarePartners revenue of $600.9 million.
• - CareDelivery revenue recorded at $33.4 million.
• - CareEnablement revenues came in at $39.6 million.
• - Total revenues showcased a significant year-over-year change, with CarePartners leading the way with a 57% spike.

Cost of services reflected $549.1 million, while total expenses were recorded at $599.8 million.

Guidance and Future Outlook

Looking ahead, Astrana provides a positive outlook for the second quarter and full-year results:

• - For the quarter ending June 30, 2025, they anticipate total revenue between $615 million and $655 million.
• - For the year ending December 31, 2025, the expected total revenue is projected between $2.5 billion and $2.7 billion.
• - Adjusted EBITDA for the same year is expected to fall within $170 million to $190 million.

Despite substantial investments in automation and artificial intelligence, the outlook remains strong, with anticipated costs in the vicinity of $15 million associated with integrations and strategic growth initiatives.

Conclusion

In summary, Astrana Health, Inc.'s Q1 2025 results indicate a strong foundation for continued growth within the healthcare landscape. With significant revenue growth, a commitment to lead in patient care through technology, and initiatives to foster an adaptable workforce, Astrana is poised for future success. Investors and stakeholders alike are eagerly awaiting the expected developments as the company progresses through 2025. For further information, visit Astrana Health.